Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Total Debt: 2019

  • Avidity Biosciences' Total Debt was N/A to $4.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was $4.5 million, marking a year-over-year change of. This contributed to the annual value of $4.5 million for FY2019, which is N/A change from last year.
  • According to the latest figures from Q4 2019, Avidity Biosciences' Total Debt is $4.5 million.
  • Over the past 5 years, Avidity Biosciences' Total Debt peaked at $4.5 million during Q4 2019, and registered a low of $4.5 million during Q4 2019.
  • Over the past 1 years, Avidity Biosciences' median Total Debt value was $4.5 million (recorded in 2019), while the average stood at $4.5 million.